Trends in rheumatic disease: Update on new diagnostic and treatment strategies

Brian F. Mandell, MD, PhD
Department of Rheumatic and Immunologic Diseases, Cleveland Clinic; Senior Associate Program Director, Internal Medicine Residency Program; Deputy Editor, Cleveland Clinic Journal of Medicine

Address: Brian F. Mandell, MD, PhD, Cleveland Clinic Journal of Medicine, NA32,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Dr. Mandell has indicated that he has received grant or research support from the Novartis, Smith-Kline, Centocor, Searle, and Merck corporations, and that this article discusses therapies that are not yet approved by the Food and Drug Administration for the use under discussion or that are still under investigation.

Brian F. Mandell, MD, PhD
Department of Rheumatic and Immunologic Diseases, Cleveland Clinic; Senior Associate Program Director, Internal Medicine Residency Program; Deputy Editor, Cleveland Clinic Journal of Medicine

Address: Brian F. Mandell, MD, PhD, Cleveland Clinic Journal of Medicine, NA32,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Dr. Mandell has indicated that he has received grant or research support from the Novartis, Smith-Kline, Centocor, Searle, and Merck corporations, and that this article discusses therapies that are not yet approved by the Food and Drug Administration for the use under discussion or that are still under investigation.

Brian F. Mandell, MD, PhD
Department of Rheumatic and Immunologic Diseases, Cleveland Clinic; Senior Associate Program Director, Internal Medicine Residency Program; Deputy Editor, Cleveland Clinic Journal of Medicine

Address: Brian F. Mandell, MD, PhD, Cleveland Clinic Journal of Medicine, NA32,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Dr. Mandell has indicated that he has received grant or research support from the Novartis, Smith-Kline, Centocor, Searle, and Merck corporations, and that this article discusses therapies that are not yet approved by the Food and Drug Administration for the use under discussion or that are still under investigation.